马应龙八宝Mabo's品牌怎么样 申请店铺

我要投票 马应龙八宝Mabo's在眼霜行业中的票数:430 更新时间:2025-05-25
马应龙八宝Mabo's是哪个国家的品牌?「马应龙八宝Mabo's」是 马应龙药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北武汉,由创始人陈平经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力马应龙八宝Mabo's品牌出海!将品牌入驻外推网,定制马应龙八宝Mabo's品牌推广信息,可以显著提高马应龙八宝Mabo's产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

马应龙八宝Mabo's怎么样

马应龙是一家经国家商务部认定的中华老字号企业,创始于公元1582年。经过多年持续快速健康发展,马应龙已经成为一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的专业化多功能国际化的医药类上市公司。

公司与北京大学药学院、中国药科大学等多家科研机构建立了长期的战略合作关系。经国家人事部核准公司与北京大学共同组建了博士后工作站。2009年,马应龙药业集团股份有限公司技术中心被国家发改委、科技部等五部委认定为国家级企业技术中心,马应龙创新药物研发团队被湖北省委组织部认定为首批“湖北省重点产业创新团队”。

马应龙及旗下子公司分别通过了国家药监局GMP、GSP质量管理规范体系认证,获得国际权威机构SGS颁发的环境管理体系ISO14000和职业安全与健康管理体系OHSAS18000的认证,在医药行业内率先实现了“三认证”。在世界品牌实验室、世界经理人周刊联合评估的2009年“中国最具价值品牌500强”排行榜中,马应龙名列第213位,品牌价值达到了40.01亿元。2006年马应龙荣获国家工商总局认定的“驰名保护”。2009年,马应龙被中国非处方药物协会评选为“中国非处方药品牌企业十五强”

公司股票于2004年在上海证券交易所上市,由此获得了持续融资的通道和规范营运的平台。2007年,公司股票被上海证券交易所、中国证券指数公司选定为中国上市公司治理指数样本股,标志着公司治理水平获得社会公众、证券机构及专家的高度认可。

传承四百多年的历史文化,公司逐步形成了具有马应龙特色的企业文化体系。公司秉承“为顾客创造健康,为股东创造财富,为员工创造机会,为社会创造效益”的经营宗旨,倡导“以真修心,以勤修为”的哲学观,倡导“稳健经营、协调发展”的经营观,倡导“资源增值”的价值观,弘扬“龙马精神”的企业精神。马应龙将以实现中药现代化为己任,在品牌经营战略的指引下与时俱进,继往开来。


Ma Yinglong is a Chinese time-honored enterprise recognized by the Ministry of Commerce. It was founded in 1582 ad. After years of sustained, rapid and healthy development, Ma Yinglong has become a professional, multi-functional and international pharmaceutical listed company involved in drug manufacturing, drug research and development, drug wholesale and retail, chain hospitals and other fields. The company has established a long-term strategic cooperation relationship with many scientific research institutions, such as the school of pharmacy of Peking University and China Pharmaceutical University. With the approval of the Ministry of personnel of the people's Republic of China, the company and Peking University jointly set up a postdoctoral workstation. In 2009, the technology center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by five ministries and commissions including the national development and Reform Commission and the Ministry of science and technology, and the R & D team of Ma Yinglong innovative drugs was recognized as the first batch of "Hubei key industry innovation team" by the Organization Department of Hubei Provincial Committee. Ma Yinglong and its subsidiaries have respectively passed the GMP and GSP quality management standard system certification issued by the State Food and drug administration, obtained the certification of ISO14000 environmental management system and OHSAS18000 occupational safety and health management system issued by the international authoritative agency SGS, and took the lead in realizing the "three certifications" in the pharmaceutical industry. In the 2009 "top 500 most valuable brands in China" list jointly evaluated by world brand laboratory and World Manager weekly, Ma Yinglong ranked 213, with the brand value reaching 4.001 billion yuan. In 2006, Ma Yinglong was awarded "famous protection" by the State Administration for Industry and commerce. In 2009, Ma Yinglong was listed on Shanghai Stock Exchange in 2004 as one of the "top 15 Chinese over-the-counter drug brand enterprises" by China over-the-counter drug association, thus obtaining a channel for continuous financing and a platform for standardized operation. In 2007, the company's stock was selected as the sample stock of China's listed corporate governance index by Shanghai Stock Exchange and China Securities Index company, marking that the level of corporate governance was highly recognized by the public, securities institutions and experts. Inheriting more than 400 years of history and culture, the company has gradually formed a corporate culture system with Ma Yinglong's characteristics. The company adheres to the business tenet of "creating health for customers, creating wealth for shareholders, creating opportunities for employees and creating benefits for the society", advocates the philosophy of "cultivating the heart with sincerity, cultivating the mind with diligence", advocates the business concept of "stable operation and coordinated development", advocates the value concept of "resource added value", and promotes the enterprise spirit of "Longma spirit". Ma Yinglong will take the modernization of traditional Chinese medicine as his duty, keep pace with the times and carry forward the past and open up the future under the guidance of brand management strategy.

本文链接: https://brand.waitui.com/92904fecd.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

科源制药:持股5%以上股东问泽鸿拟减持不超3%公司股份

科源制药5月25日公告,公司持股5%以上股东问泽鸿计划自减持计划公告之日起15个交易日后的3个月内,通过集中竞价及大宗交易方式减持公司股份不超过324.87万股,即不超过公司总股本的3%。其中,通过集中竞价交易方式减持不超过108.29万股,通过大宗交易方式减持不超过216.58万股。减持价格将根据市场价格确定,且不低于发行价。减持原因为自身资金需要。

2小时前

中信证券:核心资产定价权逐步向南转移

中信证券研报表示,本轮A股公司密集赴港IPO是出海战略、制度便利和港股流动性改善三重力量助推。优质核心资产在港股正式交易后,短期会活跃对应A股的交易,部分核心资产的定价权可能会逐步南移。这个现象的背后是港股市场的吸引力在系统性提升,一是资产供给结构和质量在持续提高,二是流动性在海外资金回流的背景下趋势性改善,从历史上看,港交所每一轮制度的改革突破都带来了顺应时代特征的牛市。未来,更多优质龙头赴港上市可能成为A股市场风格重新转向核心资产的催化剂。

2小时前

巴基斯坦为比特币挖矿分配2000兆瓦电力装机容量

巴基斯坦在全国范围内支持比特币挖矿和人工智能数据中心的第一阶段计划中,已分配2000兆瓦电力装机容量。目前该国正推动加密货币合法化并吸引外国投资。巴基斯坦财政部在一份声明中表示,这项由巴基斯坦加密货币委员会主导的计划,还将有助于实现剩余能源的货币化并创造高科技就业岗位。财政部称,萨希瓦尔(Sahiwal)、中国枢纽(China Hub)和卡西姆港(Port Qasim)等目前以15%产能运行的燃煤发电项目,预计将被改用于这一计划。(财联社)

2小时前

众生药业:子公司一类创新药RAY1225注射液两项降糖III期临床试验获伦理批件

5月25日,众生药业公告称,公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新多肽药物RAY1225注射液用于2型糖尿病(T2DM)患者的两项III期临床试验(SHINING-2和SHINING-3)获得组长单位北京大学人民医院伦理审查批件,批准项目开展。RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,具有GLP-1受体和GIP受体双重激动活性。

2小时前

存款利率跌破“1”时代,储户转战“新三金”配置

5月下旬,六大国有银行集体下调利率,一年期定存首次跌破1%,活期利率仅0.05%。近一周以来,十余家中小银行紧随大行降息步伐,将最高定存利率压至1.7%以下。部分银行同步调低大额存单利率,并下架2年期以上产品。目前大行大额存单利率多未超过1.4%。部分民营银行调降后,可购大额存单最高利率也仅为1.65%。面对低利率时代,年轻人开始寻找“存款替代”,“货币基金+债基+黄金”的“新三金”配置成为新宠。蚂蚁财富公布的数据显示,截至2025年4月底,有937万90后、00后同时配置了余额宝货币基金、债券基金、黄金基金,“新三金”浪潮持续发酵。(第一财经)

2小时前

本页详细列出关于马应龙八宝Mabo's的品牌信息,含品牌所属公司介绍,马应龙八宝Mabo's所处行业的品牌地位及优势。
咨询